Sai Life Sciences · NSE: SAILIFE · BSE: 544306
Q4 FY26 results · Jan–Mar 2026
Sai Life Sciences reported revenue from operations of ₹602.14 crore (up 3.9% from Q4 FY25) and net profit of ₹104.24 crore (up 18.1% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 602.14 | 579.51 | +3.9% | 556.46 | +8.2% |
| Other income | 15.52 | 9.60 | +61.7% | 8.38 | +85.2% |
| Total income | 617.66 | 589.11 | +4.8% | 564.84 | +9.4% |
| Profit before tax | 139.23 | 118.80 | +17.2% | 134.17 | +3.8% |
| Net profit for the period | 104.24 | 88.27 | +18.1% | 100.38 | +3.8% |
| EPS, basic (₹) | 4.93 | 4.24 | +16.3% | 4.77 | +3.4% |
| Net margin (%) | 17.3 | 15.2 | 18.0 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 594.34 | 567.01 | +4.8% | 549.18 | +8.2% |
| Other income | 15.74 | 9.82 | +60.4% | 8.45 | +86.4% |
| Total income | 610.09 | 576.83 | +5.8% | 557.63 | +9.4% |
| Profit before tax | 136.85 | 120.47 | +13.6% | 130.47 | +4.9% |
| Net profit for the period | 102.53 | 89.94 | +14.0% | 97.63 | +5.0% |
| EPS, basic (₹) | 4.85 | 4.32 | +12.3% | 4.64 | +4.5% |
| Net margin (%) | 17.3 | 15.9 | 17.8 |
Consolidated
- Filed with BSE
- 14 May 2026, 23:14 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 May 2026, 23:14 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE